SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 194 filers reported holding SAGE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,167 | +94.8% | 56,690 | +297.0% | 0.06% | +96.4% |
| Q1 2023 | $599 | -37.5% | 14,280 | -43.1% | 0.03% | -47.2% |
| Q4 2022 | $958 | -99.9% | 25,117 | -25.3% | 0.05% | -33.8% |
| Q3 2022 | $1,317,000 | -44.0% | 33,637 | -53.8% | 0.08% | -54.8% |
| Q2 2022 | $2,350,000 | +280.3% | 72,749 | +289.6% | 0.18% | +342.5% |
| Q1 2022 | $618,000 | +128.0% | 18,672 | +192.8% | 0.04% | +17.6% |
| Q4 2021 | $271,000 | +14.8% | 6,376 | +19.5% | 0.03% | +9.7% |
| Q3 2021 | $236,000 | -62.7% | 5,336 | -27.0% | 0.03% | -82.8% |
| Q4 2020 | $632,000 | -63.6% | 7,310 | -74.3% | 0.18% | -67.4% |
| Q3 2020 | $1,738,000 | -26.9% | 28,431 | -50.3% | 0.55% | -31.6% |
| Q2 2020 | $2,377,000 | +145.1% | 57,158 | +69.3% | 0.81% | +97.3% |
| Q1 2020 | $970,000 | – | 33,766 | – | 0.41% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |